| Dr Roger A Hine, MD | |
|
845 Helen Dr, Lebanon, PA 17042-7493 | |
| (717) 273-8835 | |
| (717) 202-0100 |
| Full Name | Dr Roger A Hine |
|---|---|
| Gender | Male |
| Speciality | Obstetrics/gynecology |
| Experience | 28 Years |
| Location | 845 Helen Dr, Lebanon, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124071121 | NPI | - | NPPES |
| 100774032 | Medicaid | PA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207VG0400X | Obstetrics & Gynecology - Gynecology | MD065985L (Pennsylvania) | Secondary |
| 207VX0000X | Obstetrics & Gynecology - Obstetrics | MD065985L (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Good Samaritan Hospital | Lebanon, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Wellspan Medical Group | 1951213115 | 1946 |
News Archive
Conatus Pharmaceuticals Inc. announced today the treatment of the first patient in a multi-center Phase 2b clinical trial evaluating CTS-1027 in combination with Peginterferon Alfa-2a and ribavirin in a treatment experienced, hepatitis C null responder patient population. Safety, tolerability, and antiviral activity of the triple combination will be assessed after up to 48 weeks of therapy.
Normal Pressure Hydrocephalus is a neurological condition which typically affects adults ages 55 and older. This condition was first described in the 1960s as a triad of gait disturbance, dementia, and bladder incontinence. The ventricles of the brain appear enlarged although the cerebrospinal fluid pressure remains normal.
University of Massachusetts Medical School researchers have found a way to more efficiently delivery a CRISPR/Cas9 therapeutic to adult mice with the metabolic disease Tyrosinemia type I that may also prove to be safer for use in humans.
Results presented today at the ESMO Congress 2019, Barcelona 27 September - 01 October, during the second Proffered Paper Session on Gastrointestinal tumors (colorectal) by VHIO's Director, Josep Tabernero, show that the triplet combination of the BRAF inhibitor, encorafenib, MEK inhibitor, binimetinib, and EGFR inhibitor, cetuximab, not only significantly improves overall survival but also increases objective response rates compared with standard of care in patients with BRAF V600E-mutant metastatic colorectal cancer.
› Verified 7 days ago
| Entity Name | Wellspan Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750480299 PECOS PAC ID: 1951213115 Enrollment ID: O20040220000815 |
News Archive
Conatus Pharmaceuticals Inc. announced today the treatment of the first patient in a multi-center Phase 2b clinical trial evaluating CTS-1027 in combination with Peginterferon Alfa-2a and ribavirin in a treatment experienced, hepatitis C null responder patient population. Safety, tolerability, and antiviral activity of the triple combination will be assessed after up to 48 weeks of therapy.
Normal Pressure Hydrocephalus is a neurological condition which typically affects adults ages 55 and older. This condition was first described in the 1960s as a triad of gait disturbance, dementia, and bladder incontinence. The ventricles of the brain appear enlarged although the cerebrospinal fluid pressure remains normal.
University of Massachusetts Medical School researchers have found a way to more efficiently delivery a CRISPR/Cas9 therapeutic to adult mice with the metabolic disease Tyrosinemia type I that may also prove to be safer for use in humans.
Results presented today at the ESMO Congress 2019, Barcelona 27 September - 01 October, during the second Proffered Paper Session on Gastrointestinal tumors (colorectal) by VHIO's Director, Josep Tabernero, show that the triplet combination of the BRAF inhibitor, encorafenib, MEK inhibitor, binimetinib, and EGFR inhibitor, cetuximab, not only significantly improves overall survival but also increases objective response rates compared with standard of care in patients with BRAF V600E-mutant metastatic colorectal cancer.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Roger A Hine, MD 3421 Concord Rd, York, PA 17402-9001 Ph: (717) 273-8835 | Dr Roger A Hine, MD 845 Helen Dr, Lebanon, PA 17042-7493 Ph: (717) 273-8835 |
News Archive
Conatus Pharmaceuticals Inc. announced today the treatment of the first patient in a multi-center Phase 2b clinical trial evaluating CTS-1027 in combination with Peginterferon Alfa-2a and ribavirin in a treatment experienced, hepatitis C null responder patient population. Safety, tolerability, and antiviral activity of the triple combination will be assessed after up to 48 weeks of therapy.
Normal Pressure Hydrocephalus is a neurological condition which typically affects adults ages 55 and older. This condition was first described in the 1960s as a triad of gait disturbance, dementia, and bladder incontinence. The ventricles of the brain appear enlarged although the cerebrospinal fluid pressure remains normal.
University of Massachusetts Medical School researchers have found a way to more efficiently delivery a CRISPR/Cas9 therapeutic to adult mice with the metabolic disease Tyrosinemia type I that may also prove to be safer for use in humans.
Results presented today at the ESMO Congress 2019, Barcelona 27 September - 01 October, during the second Proffered Paper Session on Gastrointestinal tumors (colorectal) by VHIO's Director, Josep Tabernero, show that the triplet combination of the BRAF inhibitor, encorafenib, MEK inhibitor, binimetinib, and EGFR inhibitor, cetuximab, not only significantly improves overall survival but also increases objective response rates compared with standard of care in patients with BRAF V600E-mutant metastatic colorectal cancer.
› Verified 7 days ago
Dr. Daniel P Rollo, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 300 Willow St, Lebanon, PA 17046 Phone: 717-273-8835 Fax: 717-273-0728 | |
Dr. Maryanne T. Mclaughlin, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 845 Helen Dr, Lebanon, PA 17042 Phone: 717-273-8835 Fax: 717-202-0100 | |
Dennis J Easter, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 845 Helen Dr, Lebanon, PA 17042 Phone: 717-273-8835 Fax: 717-202-0100 | |
Nathan Adam Keller, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 845 Helen Dr, Lebanon, PA 17042 Phone: 717-273-8835 Fax: 717-202-0100 | |
James A Nicholson, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 30 N 4th St Fl 2, Lebanon, PA 17046 Phone: 717-274-0474 Fax: 717-270-2374 | |
Dr. Raliat Oluwafunke Bashua, Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 845 Helen Dr, Lebanon, PA 17042 Phone: 717-273-8835 Fax: 717-202-0100 |